A four-year assessment of the characteristics of Rwandan FDA drug recalls

Author:

Bahizi Marcel,Nyirimigabo Eric,Ntirenganya Lazare,Umuhoza Martine Ishimwe,Habyalimana Vedaste,Bikorimana Gerard,Ukwishaka Joyeuse

Abstract

Abstract Background A drug recall is an act of removing products from the market and/or returning them to the manufacturer for disposal or correction when they violate safety laws. Action can be initiated by the manufacturing company or by the order of a regulatory body. This study aimed to assess the characteristics of Rwanda FDA drug recall and determine the association between classes of recall and recall characteristics. Methodology This was a retrospective descriptive cross-sectional study. Data about recalled drugs were collected from the official website of the Rwanda FDA in the section assigned to “Safety alerts”. The search included data reported between February 2019 and February 2023 covering four years. Data cleaning was conducted in Microsoft Excel to address missing data and inconsistencies, followed by importation into STATA/SE software version 17.0 for further cleaning and subsequent analysis. Descriptive statistics were computed for independent variables. Categorical variables were described in terms of counts and relative frequencies. Bivariate analyses used Pearson’s chi-square test to illustrate the associations between categorical independent variables and recall classes. Results The study revealed that a large proportion (33.0%) of the recalled products belonged to Class I. Antibiotics constituted 35.8% of the recalled products, with contamination emerging as a leading cause and responsible for 26.4% of the recalls. India was the leading manufacturing country for the recalled products (29.2%), followed by France (17.9%), China (17.0%), Kenya (13.2%), and Russia (6.6%). An association was found between the class of recall and several recall characteristics, including the year of recall, drug category, safety issues, reporter, and manufacturing country. Conclusion This study provides a comprehensive overview of the characteristics of drug recalls in Rwanda. The insights gained contribute to a nuanced understanding of recall dynamics and provide evidence-based strategies to enhance drug quality, safety, efficacy, regulatory compliance, and patient welfare.

Publisher

Springer Science and Business Media LLC

Reference39 articles.

1. U.S. Food and Drug Administration. RECALL PROCEDURES. In: Regulatory Procedures Manual. 2021. p. 1–153.

2. Sadhna D, Nagaich U. Drug Recall: An Incubus for Pharmaceutical Companies and Most Serious Drug Recall of History. Int J Pharm Investig. 2015;5:1–7. https://doi.org/10.4103/2230-973x.147222.

3. Vvss R, Prakash Veluchuri J, Adhikari S, Indukuri H. An Overview on Pharmaceutical Drug Recalls. The Pharmaceutical and Chemical Journal. 2020;7:16–22.

4. Hall K, Stewart T, Chang J, Kelly Freeman M. Characteristics of FDA drug recalls: a 30-month analysis. Am J Health Syst Pharm. 2016;73:235–40. https://doi.org/10.2146/ajhp150277.

5. Food and Drug Administration Recalls Backgrounds and Definitions. Available online: https://www.fda.gov/safety/industry-guidance-recalls/recalls-background-and-definitions . Accessed 22 Jan 2022.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3